Skip to main content

Table 1 Epigenetic drugs for cancer therapy approved by FDA

From: Epigenetic modulators as therapeutic targets in prostate cancer

Drug

Comercial name

Company

Class

Year of approval

Treatment type

Cancer

5-Azacytidine

Vidaza®

Celgene Corporation

DNMTi

2004

Single agent

Myelodysplastic syndrome

5-Aza-2′-deoxycytidine

Dacogen®

Eisai

DNMTi

2006

Single agent

Myelodysplastic syndrome

Vorinostat/SAHA

Zolinza®

Merck

Pan-HDACi

2006

Single agent

Cutaneous T cell lymphoma

Romidepsin

Istodax®

Celgene Corporation

Class I HDACi

2009

Single agent

Cutaneous and peripheral T cell lymphoma

Belinostat

Beleodaq®

Spectrum Pharmaceuticals, Inc.

Pan-HDACi

2014

Single agent

Peripheral T cell lymphoma

Panobinostat

Farydak®

Novartis

Pan-HDACi

2015

Combination with bortezomid and examethasone

Multiple myeloma